These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 30174892)
1. Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. Hsieh CC; Hsu HS; Li AF; Chen YJ J Thorac Dis; 2018 Jul; 10(7):4433-4444. PubMed ID: 30174892 [TBL] [Abstract][Full Text] [Related]
2. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy. Zhang F; Zhu X; Zhang Q; Zhou P; Hao L Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698 [TBL] [Abstract][Full Text] [Related]
3. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. Akutsu Y; Murakami K; Kano M; Toyozumi T; Matsumoto Y; Takahashi M; Otsuka R; Sekino N; Yokoyama M; Shiraishi T; Matsubara H Esophagus; 2018 Apr; 15(2):103-108. PubMed ID: 29892935 [TBL] [Abstract][Full Text] [Related]
4. PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma. Jiang D; Song Q; Wei X; Yu Z; Liu Y; Wang H; Wang X; Huang J; Su J; Hong Y; Xu Y; Xu C; Hou Y Front Oncol; 2022; 12():897527. PubMed ID: 35865481 [TBL] [Abstract][Full Text] [Related]
5. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas. Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Jiang Y; Lo AWI; Wong A; Chen W; Wang Y; Lin L; Xu J Oncotarget; 2017 May; 8(18):30175-30189. PubMed ID: 28404915 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma. Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796 [TBL] [Abstract][Full Text] [Related]
8. High programmed death-ligand 1 expression is a poor prognostic indicator for esophageal squamous cell carcinoma and is correlated with two-field lymph node metastasis. Liang M; Yu F; Wu W; Chen H; Zheng B; Zheng W; Zhu Y; Chen C Transl Cancer Res; 2020 Apr; 9(4):2472-2481. PubMed ID: 35117606 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis. Qu HX; Zhao LP; Zhan SH; Geng CX; Xu L; Xin YN; Jiang XJ J Thorac Dis; 2016 Nov; 8(11):3197-3204. PubMed ID: 28066599 [TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Kollmann D; Ignatova D; Jedamzik J; Chang YT; Jomrich G; Baierl A; Kazakov D; Michal M; French LE; Hoetzenecker W; Schatton T; Asari R; Preusser M; Gnant M; Guenova E; Schoppmann SF Oncoimmunology; 2018; 7(6):e1435226. PubMed ID: 29872575 [No Abstract] [Full Text] [Related]
11. Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. Kim R; Keam B; Kwon D; Ock CY; Kim M; Kim TM; Kim HJ; Jeon YK; Park IK; Kang CH; Kim DW; Kim YT; Heo DS World J Gastroenterol; 2016 Oct; 22(37):8389-8397. PubMed ID: 27729745 [TBL] [Abstract][Full Text] [Related]
12. Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma. Wang P; Chen Y; Long Q; Li Q; Tian J; Liu T; Wu Y; Ding Z J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625514 [TBL] [Abstract][Full Text] [Related]
13. Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Jiang D; Song Q; Wang H; Huang J; Wang H; Hou J; Li X; Xu Y; Sujie A; Zeng H; Tan L; Hou Y Oncotarget; 2017 Jan; 8(5):8315-8329. PubMed ID: 28039448 [TBL] [Abstract][Full Text] [Related]
14. PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma. Okadome K; Baba Y; Yasuda-Yoshihara N; Nomoto D; Yagi T; Toihata T; Ogawa K; Sawayama H; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H Cancer Sci; 2022 Feb; 113(2):399-410. PubMed ID: 34773342 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. Takamori S; Takada K; Azuma K; Jogo T; Shimokawa M; Toyokawa G; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y Ann Surg Oncol; 2019 Jun; 26(6):1916-1924. PubMed ID: 30815801 [TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Guo W; Zhang F; Shao F; Wang P; Li Z; Yang X; He Z; Shi S; Gao Y; He J Hum Pathol; 2019 Feb; 84():291-298. PubMed ID: 30296523 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of PD-L1 in esophageal squamous cell carcinoma: a meta-analysis. Guo W; Wang P; Li N; Shao F; Zhang H; Yang Z; Li R; Gao Y; He J Oncotarget; 2018 Mar; 9(17):13920-13933. PubMed ID: 29568405 [TBL] [Abstract][Full Text] [Related]
18. The expression of programed death ligand-1 could be related with unfavorable prognosis in salivary duct carcinoma. Sato F; Akiba J; Kawahara A; Naito Y; Ono T; Takase Y; Murata K; Abe H; Yamaguchi T; Miyoshi H; Abe Y; Mihara Y; Tanikawa M; Akashi M; Kurose H; Umeno H; Yano H J Oral Pathol Med; 2018 Aug; 47(7):683-690. PubMed ID: 29719073 [TBL] [Abstract][Full Text] [Related]
19. Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping. Jesinghaus M; Steiger K; Slotta-Huspenina J; Drecoll E; Pfarr N; Meyer P; Konukiewitz B; Bettstetter M; Wieczorek K; Ott K; Feith M; Langer R; Weichert W; Specht K; Boxberg M Oncotarget; 2017 Jul; 8(29):46756-46768. PubMed ID: 28657901 [TBL] [Abstract][Full Text] [Related]
20. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]